<SEC-DOCUMENT>0001738048-25-000022.txt : 20251114
<SEC-HEADER>0001738048-25-000022.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114173547
ACCESSION NUMBER:		0001738048-25-000022
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oruka Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-51477
		FILM NUMBER:		251488423

	BUSINESS ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-606-7910

	MAIL ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARCA biopharma, Inc.
		DATE OF NAME CHANGE:	20090128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Venrock Healthcare Capital Partners III, L.P.
		CENTRAL INDEX KEY:			0001738048
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		530 FIFTH AVENUE, 22ND FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-444-4100

	MAIL ADDRESS:	
		STREET 1:		530 FIFTH AVENUE, 22ND FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
		<previousAccessionNumber>0001104659-24-054266</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001738048</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>3</amendmentNo>
	      <securitiesClassTitle>Common Stock, par value $0.001 per share </securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0000907654</issuerCik>        <issuerName>ORUKA THERAPEUTICS, INC.</issuerName>        <issuerCusip>687604108</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>855 Oak Grove Avenue, Suite 100</com:street1>
                    <com:city>Menlo Park</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94025 </com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   				        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
		      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Venrock Healthcare Capital Partners III, L.P.</reportingPersonName>

	  		<memberGroup>a</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4909619.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4909619.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4909619.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>9.9</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>VHCP Co-Investment Holdings III, LLC</reportingPersonName>

	  		<memberGroup>a</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4909619.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4909619.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4909619.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>9.9</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Venrock Healthcare Capital Partners EG, L.P.</reportingPersonName>

	  		<memberGroup>a</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4909619.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4909619.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4909619.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>9.9</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>VHCP Management III, LLC</reportingPersonName>

	  		<memberGroup>a</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4909619.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4909619.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4909619.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>9.9</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>VHCP Management EG, LLC</reportingPersonName>

	  		<memberGroup>a</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4909619.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4909619.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4909619.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>9.9</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Nimish Shah</reportingPersonName>

	  		<memberGroup>a</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4909619.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4909619.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4909619.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>9.9</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Bong Y. Koh</reportingPersonName>

	  		<memberGroup>a</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>4909619.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>4909619.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4909619.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>9.9</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>ORUKA THERAPEUTICS, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>855 Oak Grove Avenue, Suite 100, Menlo Park, CA, 94025 .</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>The names of the persons filing this report (collectively, the "Reporting Persons") are:

Venrock Healthcare Capital Partners III, L.P. ("VHCP III")
VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III")
Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG")
VHCP Management III, LLC ("VHCP Management III")
VHCP Management EG, LLC ("VHCP Management EG")
Nimish Shah ("Shah")
Bong Koh ("Koh")

The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.
</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>New York Office:
7 Bryant Park, 23rd Floor
New York, NY 10018

Palo Alto Office:
3340 Hillview Avenue
Palo Alto, CA 94304
</principalBusinessOfficeOrResidenceAddress>        <citizenship>All of the entities were organized in Delaware. Shah and Koh are both United States citizens.</citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.

The Reporting Persons' ownership of the Issuer's securities consists of (i) 856,747 shares of common stock and pre-funded warrants (the "Pre-Funded Warrants") exercisable for up to 330,615 shares of common stock held by VHCP III, (ii) 85,816 shares of common stock and Pre-Funded Warrants exercisable for up to 33,068 shares of common stock held by VHCP Co-Investment III, and (iii) 3,205,865 shares of common stock and Pre-Funded Warrants exercisable for up to 1,227,526 shares of common stock held by VHCP EG. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker"), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, VHCP III, VHCP Co-Investment III and VHCP EG, together with their affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding. VHCP III, VHCP Co- Investment III and VHCP EG are currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 4,909,619 shares of common stock.

VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.</amountBeneficiallyOwned>    <classPercent>Due to the Beneficial Ownership Blocker in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage is 9.99%. Such percentage is based upon 48,384,150 shares of common stock outstanding as of September 19, 2025, as reported in the Issuer's prospectus dated November 3, 2025 filed with the Securities and Exchange Commission (the "SEC") on November 11, 2025; (ii) 761,191 shares of common stock issuable upon the exercise of Pre-Funded Warrants. Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of the Reporting Persons' cover pages have been rounded down to 9.9%.</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>

		<exhibitInfo>Exhibit 24.1	Power of Attorney for Nimish Shah, dated April 29, 2024  (incorporated by reference to Exhibit B to Schedule 13G filed on April 29, 2024)

Exhibit 24.2	Power of Attorney for Bong Koh, dated April 29, 2024 (incorporated by reference to Exhibit C to Schedule 13G filed on April 29, 2024)

Exhibit 99.1	Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on February 27, 2025)
</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>Venrock Healthcare Capital Partners III, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Sherman G. Souther</signature>
        <title>By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>VHCP Co-Investment Holdings III, LLC</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Sherman G. Souther</signature>
        <title>By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Venrock Healthcare Capital Partners EG, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Sherman G. Souther</signature>
        <title>By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>VHCP Management III, LLC</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Sherman G. Souther</signature>
        <title>By Sherman G. Souther, Authorized Signatory</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>VHCP Management EG, LLC</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Sherman G. Souther</signature>
        <title>By Sherman G. Souther, Authorized Signatory</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Nimish Shah</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Sherman G. Souther</signature>
        <title>By Sherman G. Souther, Attorney-in-fact</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Bong Y. Koh</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Sherman G. Souther</signature>
        <title>By Sherman G. Souther, Attorney-in-fact</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>

    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
